A Phase 2 interventional study of B244 and Vehicle in Acne Vulgaris, sponsored by AOBiome LLC. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 2b, randomized, double-blind, vehicle-controlled clinical trial evaluating the efficacy, safety, and tolerability of B244 compared to vehicle in the treatment of moderate to severe acne vulgaris in adolescents and adults. Participants who meet the study entry criteria will be randomized in a 1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0 or vehicle (control) for 12 weeks.
This is a 16-week, phase 2b, multicenter, randomized, double-blind, vehicle-controlled study to assess the efficacy, safety, and tolerability of B244 for the treatment of moderate to severe acne vulgaris (IGA 3-4) in adolescents (ages 12 to \<18 years) and adults (ages ≥18 years).
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
This study's planned enrollment of 176 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Browse Acne Vulgaris studies →AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of moderate to severe facial acne vulgaris defined as the following at Screening and Baseline:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One arm of 88 Subjects will be receiving a dose of B244 O.D. 5.0 suspension
Biological: B244
Second arm of 88 subjects will receive a vehicle dosing
Biological: Vehicle
B244 suspension
Vehicle suspension
Proportion of participants with IGA success, defined as IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement
The Investigator Global Assessment (IGA) is a validated 5-point static scale (0 = Clear to 4 = Severe) used to rate the overall severity of facial acne vulgaris at each assessment timepoint.
Time frame: Baseline to Week 12
Mean change in log inflammatory lesion count
Inflammatory lesions are defined as papules, pustules, and nodules (cysts are excluded from eligibility). The inflammatory lesion count provides a continuous, objective, quantitative measure of disease activity that is sensitive to treatment effects and endorsed by the FDA as a co-primary or key secondary endpoint in acne drug development. The mean change in log-transformed lesion count corresponds to a geometric mean ratio, which can be interpreted as a proportional reduction in inflammatory burden.
Time frame: Baseline to Week 12
Mean change in absolute lesion count
Absolute lesion count changes complement the log-transformed analysis by providing directly interpretable counts of lesion reductions.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in log inflammatory lesion count
Inflammatory lesions are defined as papules, pustules, and nodules (cysts are excluded from eligibility). The inflammatory lesion count provides a continuous, objective, quantitative measure of disease activity that is sensitive to treatment effects and endorsed by the FDA as a co-primary or key secondary endpoint in acne drug development. The mean change in log-transformed lesion count corresponds to a geometric mean ratio, which can be interpreted as a proportional reduction in inflammatory burden.
Time frame: Baseline to Week 2, 4, 8, 16
Percent change in inflammatory lesion count
Inflammatory lesions are defined as papules, pustules, and nodules (cysts are excluded from eligibility). The inflammatory lesion count provides a continuous, objective, quantitative measure of disease activity that is sensitive to treatment effects and endorsed by the FDA as a co-primary or key secondary endpoint in acne drug development. The mean change in log-transformed lesion count corresponds to a geometric mean ratio, which can be interpreted as a proportional reduction in inflammatory burden.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Proportion of participants with IGA 0 (clear) or 1 (almost clear) and ≥2-point improvement
The Investigator Global Assessment (IGA) is a validated 5-point static scale (0 = Clear to 4 = Severe) used to rate the overall severity of facial acne vulgaris at each assessment timepoint.
Time frame: Baseline to Week 2, 4, 8, 16
Proportion of participants with IGA 0 (clear) or 1 (almost clear)
The Investigator Global Assessment (IGA) is a validated 5-point static scale (0 = Clear to 4 = Severe) used to rate the overall severity of facial acne vulgaris at each assessment timepoint.
Time frame: Week 2, 4, 8, 12, 16
Mean change in absolute and log total lesion count
Lesion count data are log-transformed prior to analysis to normalize the characteristically right- skewed distribution of count data. The mean change in log-transformed lesion count corresponds to a geometric mean ratio, which can be interpreted as a proportional reduction in inflammatory burden. Absolute lesion count changes complement the log-transformed analysis by providing directly interpretable counts of lesion reductions.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Percent change in total lesion count
The total lesion count is the sum of total inflammatory and total non-inflammatory lesion counts.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in absolute and log non-inflammatory lesion count
Absolute lesion count changes complement the log-transformed analysis by providing directly interpretable counts of lesion reductions. Non-inflammatory lesion counts capture comedone burden, which is an important component of acne pathophysiology that may respond differently to treatment than inflammatory lesions.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Percent change in non-inflammatory lesion count
Non-inflammatory lesion counts capture comedone burden, which is an important component of acne pathophysiology that may respond differently to treatment than inflammatory lesions. Non-inflammatory lesions: open comedones (blackheads) and closed comedones (whiteheads) (counted separately; summed as total non-inflammatory lesion count).
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in number of nodules
Nodule count changes provide specific information on the most severe acne lesion type.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in Skindex-16
The Skindex-16 is a validated, 16-item, dermatology-specific patient-reported outcome instrument assessing the impact of skin disease on health-related quality of life over the past week. Items are grouped into three domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). Each item is scored on a 7-point scale (0 = Never Bothered to 6 = Always Bothered), which is then multiplied by 16.667 to transform responses to a 0 100 scale; domain scores and total score are expressed on a 0-100 scale (higher scores = greater burden).
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in DLQI/CDLQI
The Dermatology Life Quality Index (DLQI)/ Children's Dermatology Life Quality Index (CDLQI) are validated 10-item dermatology-specific quality-of-life questionnaires scored 0-30; higher scores indicate greater disease impact. DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. CDLQI is designed to measure the impact of any skin disease on the lives of children.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in EQ-5D-5L
The EQ-5D-5L (Euro Quality of life 5 Dimension 5 Level) is a validated, self administered, generic health status measure assessing five dimensions on a 5-level scale (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) plus a 0-100 VAS for overall current health state today from 0 (worst imaginable) to 100 (best imaginable).
Time frame: Baseline to Week 2, 4, 8, 12, 16
Mean change in Patient Global Impression of Severity (PGIS) score
The Patient Global Impression of Severity (PGIS) is a single-item PRO on which participants rate the severity of their acne right now on a 7-point scale ranging from 1 = Not Present to 7 = Extremely Severe, providing participant perspective complementary to the investigator-assessed IGA.
Time frame: Baseline to Week 2, 4, 8, 12, 16
Proportion of participants with a PGIS score of 1 (not present) or 2 (very mild) at Week 2, 4, 8, 12, 16 who did not report a PGIS score of 1 or 2 at Baseline
The Patient Global Impression of Severity (PGIS) is a single-item PRO on which participants rate the severity of their acne right now on a 7-point scale ranging from 1 = Not Present to 7 = Extremely Severe, providing participant perspective complementary to the investigator-assessed IGA.
Time frame: Week 2, 4, 8, 12, 16
Mean Patient Global Impression of Change (PGIC) score
The Patient Global Impression of Change (PGIC) is a single-item PRO on which participants rate the overall change in their acne since the start of treatment on a 7-point scale (1=Very Much Improved to 7=Very Much Worse). PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment depicting a participant's rating of overall improvement.
Time frame: Week 2, 4, 8, 12, 16
Proportion of participants with a PGIC score of 1 (very much improved) or 2 (much improved)
The Patient Global Impression of Change (PGIC) is a single-item PRO on which participants rate the overall change in their acne since the start of treatment on a 7-point scale (1=Very Much Improved to 7=Very Much Worse). PGIC is a participants' self-reporting measure that reflects their belief about the efficacy of treatment depicting a participant's rating of overall improvement.
Time frame: Week 2, 4, 8, 12, 16
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Aug 2027, 10 months later.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 10 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC